Complete List of Cannabinoids in Cannabis

Published March 12, 2026 by Christopher Lynch

This page summarizes cannabinoid research from peer-reviewed literature. Evidence strength varies widely between compounds. Some cannabinoids are well studied, while others are primarily known through phytochemical identification.

Cannabis chemistry is often reduced to two names: THC and CBD. In reality, the plant produces a much broader family of naturally occurring cannabinoids, including major cannabinoids, minor cannabinoids, acidic precursor cannabinoids, varin and phorol homologues, oxidation products, and structurally transformed compounds. A complete cannabinoid reference needs to reflect that broader chemistry.

This page focuses on naturally occurring phytocannabinoids found in cannabis. That includes cannabinoids that appear directly in plant biosynthesis, cannabinoids that occur in acidic precursor form, and cannabinoids that arise naturally through oxidation, aging, or structural transformation. It does not attempt to catalog synthetic cannabinoids. The goal is to create a reader-facing scientific reference that is useful for understanding the plant itself.

One of the most important points to understand up front is that cannabis often produces cannabinoids in acidic forms, such as THCA, CBDA, and CBGA. Heat can later convert some of these into more familiar neutral cannabinoids such as THC and CBD. Another important point is that not every named cannabinoid is equally studied. Some compounds, such as THC, CBD, CBG, CBC, CBN, THCV, and CBDV, appear in broader pharmacology discussions. Others are known mainly through phytochemical identification and classification rather than meaningful benefit-specific literature.

What Are Cannabinoids?

Cannabinoids are compounds associated with cannabis and the body’s endocannabinoid system. In broad scientific usage, the term can refer to phytocannabinoids made by the plant, endocannabinoids made by the body, and synthetic cannabinoids made in laboratories. This page is specifically about phytocannabinoids that occur naturally in cannabis.

Public-facing cannabis education often stops at THC and CBD, but serious cannabinoid chemistry goes much further. Reviews commonly describe cannabis as containing well over 100 cannabinoids, with many additional compounds beyond the few that dominate commercial awareness. Some of these cannabinoids are better known because they occur in larger amounts or have been studied more extensively. Others are known mainly because phytochemical work has identified them in the plant, even if pharmacology and benefit-specific research remain limited.

Natural Phytocannabinoids vs Synthetic Cannabinoids

This page is intentionally limited to cannabinoids that occur naturally in cannabis. Synthetic cannabinoids are outside scope. That distinction is important because the chemistry, pharmacology, safety profile, and regulatory treatment of synthetic cannabinoids are not the same as those of naturally occurring phytocannabinoids.

Delta-8 THC is worth calling out because it sits at the center of a lot of confusion. It does occur naturally in cannabis, but generally in low concentrations. That means it belongs on a complete natural cannabinoid list, even though many commercial delta-8 products are manufactured through conversion processes because natural concentrations are not usually high enough to support large-scale extraction.

Structural Classification Chart

Chart 1. Structural classification of the main cannabinoid families emphasized on this page.

Biosynthesis Pathway Chart

One of the best ways to understand cannabinoid diversity is to start with biosynthesis. CBGA is commonly described as a central precursor in the cannabinoid biosynthetic pathway. From there, plant enzymes contribute to the formation of acidic cannabinoids such as THCA, CBDA, and CBCA, which can later convert into neutral cannabinoids under heat.

Chart 2. Simplified cannabinoid biosynthesis centered on acidic precursor chemistry.

Cannabigerols

The cannabigerol family sits near the center of cannabinoid biosynthesis and is one of the most important families for understanding how cannabis chemistry is built.

• Cannabigerolic acid (CBGA) — central acidic precursor in cannabinoid biosynthesis. It matters primarily because it sits upstream of THCA, CBDA, and CBCA formation. Benefit-specific claims are not the main reason CBGA is discussed; its biosynthetic role is.
• Cannabigerol (CBG) — neutral minor cannabinoid often discussed beyond THC and CBD. It is being studied for anti-inflammatory, analgesic, neurobiological, and antimicrobial effects, but human evidence is still limited.
• Cannabigerovarin (CBGV) — varin analogue in the CBG family. Published pharmacology is far more limited than for CBG, so any benefit discussion should be treated as preliminary.
• Cannabigerovarinic acid (CBGVA) — acidic varin precursor connected to the biosynthetic branch that leads to varin cannabinoids. Benefit-specific literature is limited.
• Cannabigerol monomethylether (CBGM) — methylated CBG-family cannabinoid identified in phytochemical inventories. Published therapeutic literature is limited.
• Cannabigerolic acid monomethylether (CBGAM) — methylated acidic member of the family. Primarily relevant as part of phytochemical classification rather than benefit-specific discussion.

Cannabidiols

The cannabidiol family is widely recognized because CBD is one of the most visible cannabinoids in hemp and cannabis, but the family extends well beyond CBD alone.

• Cannabidiol (CBD) — the best-known non-intoxicating cannabinoid. It has one of the largest evidence bases among cannabis-derived compounds and is being studied across pain, inflammation, seizure-related disorders, anxiety-related symptoms, and other areas, though evidence strength varies widely by condition and product type.
• Cannabidiol monomethylether (CBDM) — methylated CBD-family cannabinoid identified in phytochemical literature. Published benefit-specific data are limited.
• Cannabidiolic acid (CBDA) — acidic precursor to CBD. It is being studied for anti-inflammatory, antiemetic, and other pharmacological properties, but the evidence base is smaller than for CBD.
• Cannabidivarinic acid (CBDVA) — acidic varin analogue in the CBD family and precursor to CBDV. Published benefit-specific data are limited.
• Cannabidiorcol (CBD-C1) — shortened side-chain homologue in the CBD family. Primarily relevant to phytochemical classification; benefit-specific data are limited.
• Cannabidivarin (CBDV) — varin analogue related to CBD. It is being studied for neurological applications and seizure-related questions, but evidence remains less mature than for CBD.
• Cannabidiphorol (CBDP) — phorol-related member of the CBD family. Interest is largely structural and pharmacological at this stage; benefit-specific evidence remains limited.

Cannabichromenes

The cannabichromene family is a core part of minor-cannabinoid chemistry and is useful for understanding how cannabinoid diversity extends beyond the THC/CBD axis.

• Cannabichromene (CBC) — better-known minor cannabinoid often included in broader pharmacology reviews. It is being studied for anti-inflammatory, pain-related, neurobiological, and skin-related effects, though strong human evidence is still limited.
• Cannabichromevarinic acid (CBCVA) — acidic varin-related member of the CBC family. Published benefit-specific data are limited.
• Cannabichromenic acid (CBCA) — acidic precursor to CBC and part of the plant-side cannabinoid profile. Benefit-specific literature is more limited than for CBC.
• Cannabichromevarin (CBCV) — varin analogue in the CBC family. Published benefit-specific evidence is limited.

Cannabinols and Cannabinodiols

This family helps illustrate that cannabinoid chemistry can include oxidation-related or transformation-associated compounds in addition to direct biosynthetic products.

• Cannabinolic acid (CBNA) — acidic member of the cannabinol family. Primarily relevant as part of advanced phytochemical classification.
• Cannabinodiol (CBND) — cannabinoid identified in advanced reference inventories. Published benefit-specific data are limited.
• Cannabinodivarin (CBVD) — varin-related member of the family. Published benefit-specific data are limited.
• Cannabinol (CBN) — widely recognized minor cannabinoid often associated in consumer discussions with sleep. It is being studied for neurobiological, anti-inflammatory, and other effects, but the evidence base is still developing and should not be overstated.
• Cannabiorcol (CBN-C1) — shortened-chain homologue in the CBN family. Mainly of phytochemical interest at present.
• Cannabivarin (CBV) — varin-related cannabinoid in the CBN/CBV grouping. Published benefit-specific literature is limited.
• Cannabinol methylether (CBNM) — methylated member of the family. Primarily relevant to structural classification.
• Cannabinol-C2 (CBN-C2) — side-chain variant in the cannabinol family with limited benefit-specific literature.
• Cannabinol-C4 (CBN-C4) — longer-chain variant in the family, primarily relevant to chemical classification.

Cannabicyclols

The cannabicyclol family reflects structural transformation chemistry and belongs in a complete natural cannabinoid reference even though it is less visible in mainstream education.

• Cannabicyclolic acid (CBLA) — acidic member of the cannabicyclol family. Published benefit-specific research is limited.
• Cannabicyclol (CBL) — cannabinoid associated with transformation chemistry and advanced phytochemical classification. Benefit-specific data are limited.
• Cannabicyclovarin (CBLV) — varin analogue within the family. Primarily of structural and taxonomic interest.

Cannabielsoins

Cannabielsoins are less familiar to most readers but are part of naturally occurring cannabinoid reference work and belong in a serious inventory of plant cannabinoids.

• Cannabielsoin (CBE) — specialized cannabinoid identified in phytochemical studies. Benefit-specific evidence is limited.
• Cannabielsoin acid A (CBEA-A) — acidic member of the family. Mainly relevant to phytochemical categorization.
• Cannabielsoic acid B (CBEA-B) — another acidic cannabielsoin form, primarily important for complete reference work.

Cannabitriols

Cannabitriols are hydroxylated cannabinoids that tend to appear in advanced phytochemical inventories rather than ordinary consumer education.

• 10-Ethoxy-9-hydroxy-delta-6a-tetrahydrocannabinol — advanced hydroxylated derivative listed in cannabinoid reference chemistry. Benefit-specific evidence is limited.
• 8,9-Dihydroxy-delta-6a-tetrahydrocannabinol — another hydroxylated cannabinoid derivative identified in phytochemical work. Benefit-specific evidence is limited.
• Cannabitriol (CBT) — named member of the cannabitriol family, mainly relevant to advanced cannabinoid inventories rather than well-developed pharmacology.
• Cannabitriolvarin (CBTV) — varin analogue within the cannabitriol family. Published benefit-specific literature is limited.

Delta-8 Tetrahydrocannabinols

Delta-8 cannabinoids belong in a complete natural cannabinoid inventory, but they should be described carefully.

• Delta-8-tetrahydrocannabinol (Δ8-THC) — naturally occurring cannabinoid isomer that generally appears in low concentrations in cannabis. It is psychoactive and intoxicating, but most commercial delta-8 exposure is likely far higher than what naturally occurs in raw plant extracts. It is not a synthetic cannabinoid, but large-scale commercial products often involve conversion rather than direct high-yield extraction from the plant.
• Delta-8-tetrahydrocannabinolic acid (Δ8-THCA) — acidic counterpart in the delta-8 family. Published benefit-specific literature is limited.

Delta-9 Tetrahydrocannabinols

The delta-9 family is the most recognized cannabinoid family in cannabis and includes both familiar consumer-facing compounds and lesser-known homologues.

• Delta-9-tetrahydrocannabinol (THC) — the best-known intoxicating cannabinoid. It has one of the most extensive research literatures among phytocannabinoids and is studied across pain, appetite, nausea, spasticity, and multiple other areas, though benefit and risk depend heavily on dose, route, formulation, and context.
• Delta-9-tetrahydrocannabinol-C4 (THC-C4) — homologue in the THC family. Primarily relevant to phytochemical classification.
• Delta-9-tetrahydrocannabiorcol (THC-C1) — shortened-chain THC-family homologue. Published benefit-specific data are limited.
• Delta-9-tetrahydrocannabiorcolic acid (THCA-C1) — acidic counterpart of THC-C1. Mainly relevant to advanced reference work.
• Delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4) — acidic C4 homologue in the THC family. Benefit-specific evidence is limited.
• Delta-9-tetrahydrocannabivarin (THCV) — varin analogue of THC and one of the better-known rare cannabinoids. It is being studied for appetite, metabolism, glycemic regulation, and neurobiological effects, but the evidence base remains mixed and still developing.
• Delta-9-tetrahydrocannabivarinic acid (THCVA) — acidic precursor to THCV and part of the varin pathway. Published benefit-specific literature is limited.
• Delta-9-tetrahydrocannabinolic acid A (THCA-A) — one of the most important acidic cannabinoids in cannabis because it is the major precursor to THC in plant material. It is being studied for anti-inflammatory, neuroprotective, and antiemetic questions, but clinical evidence remains limited.
• Delta-9-tetrahydrocannabinolic acid B (THCA-B) — alternate acidic form within the THCA grouping. More relevant to cannabinoid chemistry than to mature therapeutic literature.
• Delta-9-tetrahydrocannabiphorol (THCP) — phorol-related THC-family homologue that drew attention because of receptor-binding discussions. It is pharmacologically interesting, but human benefit-specific evidence remains very limited.

Master Cannabinoid Table

Table 1. Master list of requested naturally occurring cannabinoids with brief description and conservative research-status language.

Why This Page Stays Conservative on Benefits

A cannabinoid reference page should separate identification from evidence strength. Some cannabinoids are discussed in meaningful pharmacology reviews. Others are primarily documented because they have been isolated, named, and structurally described. Treating those two situations as though they have equal clinical relevance would be misleading.

That is why this page uses different kinds of language for different compounds. For cannabinoids such as THC, CBD, CBG, CBC, CBN, THCV, CBDV, THCA, and CBDA, it is reasonable to say they are “being studied for” certain effects or conditions. For many of the more obscure compounds, the scientifically honest position is that published benefit-specific data are limited.

Final Thoughts

A complete list of cannabinoids in cannabis is not just a glossary of acronyms. It is a map of the plant’s chemistry. THC and CBD remain the best-known names, but a scientifically useful picture also includes CBGA and the biosynthetic families built from it, acidic cannabinoids such as THCA and CBDA, minor cannabinoids such as CBG and CBC, research-focused rare cannabinoids such as THCV and THCP, naturally occurring low-abundance compounds such as delta-8 THC, and advanced families such as cannabicyclols, cannabielsoins, and cannabitriols.

Organized by family, these cannabinoids become easier to understand as part of a coherent chemical system rather than a random list of names. That is the best foundation for serious cannabinoid education and the best way to keep the language aligned with a science-first THS voice.